Additional file 1 of Associations of continuous glucose monitoring-assessed glucose variability with intima-media thickness and ultrasonic tissue characteristics of the carotid arteries: a cross-sectional analysis in patients with type 2 diabetes
Creators: name: Taya, Naohiro
name: Katakami, Naoto
name: Mita, Tomoya
name: Okada, Yosuke
name: Wakasugi, Satomi
name: Yoshii, Hidenori
name: Shiraiwa, Toshihiko
name: Otsuka, Akihito
name: Umayahara, Yutaka
name: Ryomoto, Kayoko
name: Hatazaki, Masahiro
name: Tetsuyuki Yasuda
name: Tsunehiko Yamamoto
name: Gosho, Masahiko
name: Iichiro Shimomura
name: Watada, Hirotaka
Publisher: name: figshare
Year: 2021
Subjects: subject: Medicine
subject: Genetics
subject: FOS: Biological sciences
subject: FOS: Biological sciences
subject: Physiology
subject: 59999 Environmental Sciences not elsewhere classified
subject: FOS: Earth and related environmental sciences
subject: FOS: Earth and related environmental sciences
subject: 39999 Chemical Sciences not elsewhere classified
subject: FOS: Chemical sciences
subject: FOS: Chemical sciences
subject: Sociology
subject: FOS: Sociology
subject: FOS: Sociology
subject: 19999 Mathematical Sciences not elsewhere classified
subject: FOS: Mathematics
subject: FOS: Mathematics
subject: Cancer

description: Additional file 1: Table S1. Clinical characteristics of the participants of the multicenter prospective observational cohort study. Table S2. Comparisons of clinical parameters among thickened lesion-gray-scale median tertiles. Table S3. Comparisons of clinical parameters among plaque-gray-scale median tertiles. Table S4. Associations of the metrics of continuous glucose monitoring with thickened lesion-gray-scale median and plaque-gray-scale median. Table S5. Associations between the adjustment factors in the multivariable regression models. Table S6. Associations of the metrics of continuous glucose monitoring with intima-media thickness among the participants with hypertension. Table S7. Associations of the metrics of continuous glucose monitoring with gray-scale median among the participants with hypertension. Table S8. Associations of the metrics of continuous glucose monitoring with intima-media thickness among the participants without hypertension. Table S9. Associations of the metrics of continuous glucose monitoring with gray-scale median among the participants without hypertension. Table S10. Associations of the metrics of continuous glucose monitoring with intima-media thickness among the participants with dyslipidemia. Table S11. Associations of the metrics of continuous glucose monitoring with gray-scale median among the participants with dyslipidemia. Table S12. Associations of the metrics of continuous glucose monitoring with intima-media thickness among the participants without dyslipidemia. Table S13. Associations of the metrics of continuous glucose monitoring with gray-scale median among the participants without dyslipidemia. Table S14. Associations of the metrics of continuous glucose monitoring with intima-media thickness among participants using anti-diabetic medications. Table S15. Associations of the metrics of continuous glucose monitoring with gray-scale median among participants using anti-diabetic medications. Table S16. Associations of the metrics of continuous glucose monitoring with intima-media thickness among participants not using anti-diabetic medications. Table S17. Associations of the metrics of continuous glucose monitoring with gray-scale median among participants not using anti-diabetic medications. Table S18. Associations of the metrics of continuous glucose monitoring with intima-media thickness among participants using insulin therapy. Table S19. Associations of the metrics of continuous glucose monitoring with gray-scale median among participants using insulin therapy. Table S20. Associations of the metrics of continuous glucose monitoring with intima-media thickness among participants not using insulin therapy. Table S21. Associations of the metrics of continuous glucose monitoring with gray-scale median among participants not using insulin therapy. Table S22. Associations of the metrics of continuous glucose monitoring with intima-media thickness among participants using angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers. Table S23. Associations of the metrics of continuous glucose monitoring with gray-scale median among participants using angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers. Table S24. Associations of the metrics of continuous glucose monitoring with intima-media thickness among participants not using angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers. Table S25. Associations of the metrics of continuous glucose monitoring with gray-scale median among participants not using angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers. Table S26. Associations of the metrics of continuous glucose monitoring with intima-media thickness among participants using statins. Table S27. Associations of the metrics of continuous glucose monitoring with gray-scale median among participants using statins. Table S28. Associations of the metrics of continuous glucose monitoring with intima-media thickness among participants not using statins. Table S29. Associations of the metrics of continuous glucose monitoring with gray-scale median among participants not using statins. Table S30. List of sites and investigators.